NCT00260702View on ClinicalTrials.gov

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 24, 2005

Primary Completion Date

March 19, 2010

Study Completion Date

March 19, 2010

Conditions
Hyper-IgE SyndromeJob's Syndrome
Interventions
DRUG

Omalizumab (Xolair)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00260702 - Omalizumab to Treat Hyper-IgE (Job's) Syndrome | Biotech Hunter | Biotech Hunter